

FMC CORP  
Form 8-K  
July 24, 2013

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 8-K

---

CURRENT REPORT

Pursuant to Section 13 or 15 (d) of the  
Securities Exchange Act of 1934  
Date of Report (Date of earliest event reported) July 24, 2013

---

FMC CORPORATION  
(Exact name of registrant as specified in its charter)

---

|   |                                |   |
|---|--------------------------------|---|
| Delaware  | 1-2376                         | 94-0479804                              |
| (State or other jurisdiction of<br>incorporation or organization) | (Commission<br>File<br>Number) | (I.R.S. Employer<br>Identification No.) |

|  |            |
|--|------------|
| 1735 Market Street<br>Philadelphia, Pennsylvania | 19103      |
| (Address of principal executive offices)         | (Zip Code) |

Registrant's telephone number, including area code: 215-299-6000

---

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act
  - Soliciting material pursuant to Rule 14a-2 under the Exchange Act
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
-

ITEM 7.01. REGULATION FD DISCLOSURE

On July 24, 2013, FMC Corporation issued a press release announcing that it has acquired all of the shares of Epax Nutra Holding III AS (Norway) and Epax UK Holding III AS (United Kingdom) (together, “Epax”), a leading manufacturer of high purity, premium grade Omega-3 fatty acid concentrates that are used in nutraceuticals, pharmaceuticals and food. Epax was part of Trygg Pharma Group AS (“Trygg Pharma”), an Omega-3 pharmaceutical company. This acquisition strengthens and expands FMC's presence in the high growth nutraceutical market. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

99.1 Press Release

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

FMC CORPORATION  
(Registrant)

By: /S/ PAUL W. GRAVES  
Paul W. Graves  
Executive Vice President and  
Chief Financial Officer

Date: July 24, 2013

---

EXHIBIT INDEX

| Exhibit<br>No. | Exhibit Description |
|----------------|---------------------|
|----------------|---------------------|

|      |               |
|------|---------------|
| 99.1 | Press Release |
|------|---------------|